Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.61 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.61 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428655 | 0.82 | FKBP1A (0.70) | KDM4EALDH1A1SMN1; SMN2FKBP1APOLB | |
| SCHEMBL5064329 | 0.78 | KDM4E (0.60) | KDM4EHTTALDH1A1HSD17B10HPGD | |
| SCHEMBL31428591 | 0.76 | FKBP1A (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2FKBP1A | |
| SCHEMBL1100987 | 0.75 | PIK3CD (0.53) | KDM4ESMN1; SMN2SCN9ASCN5APOLB | |
| SCHEMBL9284192 | 0.75 | MAPT (0.68) | KDM4EHTTALDH1A1HSD17B10HPGD | |
| SCHEMBL45506 | 0.75 | MAPT (0.68) | KDM4EHTTALDH1A1HSD17B10HPGD | |
| SCHEMBL6984881 | 0.75 | GRM4 (0.54) | KDM4EHTTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12988518 | 0.75 | FKBP1A (0.71) | KDM4EALDH1A1SMN1; SMN2FKBP1APOLB | |
| Hydrochloric Acid SCHEMBL1101288 | 0.74 | PIK3CD (0.52) | KDM4ESMN1; SMN2SCN9ASCN5APOLB | |
| SCHEMBL1101138 | 0.74 | KDM4E (0.58) | KDM4ESMN1; SMN2TSHRMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | claimed |
| JP-4267920-B2 | — | — | 2009-05-27 | — | — | JP | claimed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | claimed |
| JP-2004523542-A | — | — | 2004-08-05 | — | — | JP | claimed |
| EP-1377290-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-07 | — | — | EP | claimed |
| WO-2002064136-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-22 | — | — | WO | claimed |
| EP-0869958-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| WO-1998014447-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-04-09 | — | — | WO | claimed |
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| WO-2008073519-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | KDM4E 1680/4885HTT 4489/4885ALDH1A1 2449/4885 |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | KDM4E 1680/4885HTT 4489/4885ALDH1A1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.